Chlorambucil cytotoxicity in malignant B lymphocytes is synergistically increased by 2-(morpholin-4-yl)-benzo[h]chomen-4-one (NU7026)-mediated inhibition of DNA double-strand break repair via inhibition of DNA-dependent protein kinase

Journal of Pharmacology and Experimental Therapeutics

Volumn 321, Issue 3, 2007, Pages 848-855

  Amrein, Lilian ^a   Loignon, Martin ^a   Goulet, Anne Christine ^a   Dunn, Michael ^a   Jean Claude, Bertrand ^b   Aloyz, Raquel ^a   Panasci, Lawrence ^a  

^a MCGILL UNIVERSITY   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 (MORPHOLIN 4 YL) BENZO[H]CHOMEN 4 ONE; BENZENE DERIVATIVE; CHLORAMBUCIL; DNA DEPENDENT PROTEIN KINASE; DOUBLE STRANDED DNA; UNCLASSIFIED DRUG;

ARTICLE; B CELL LYMPHOMA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DNA REPAIR; DNA STRAND BREAKAGE; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; PRIORITY JOURNAL;

APOPTOSIS; B-LYMPHOCYTES; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHLORAMBUCIL; CHROMONES; DNA REPAIR; DNA-ACTIVATED PROTEIN KINASE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENZYME INHIBITORS; HISTONES; HUMANS; INHIBITORY CONCENTRATION 50; MORPHOLINES; PHOSPHORYLATION;

EID: 34248594725     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.118356     Document Type: Article

References (36)

1. Allen C, Halbrook J, and Nickoloff JA (2003) Interactive competition between homologous recombination and non-homologous end joining. Mol Cancer Res 1:913-920.
2. Aloyz R, Grzywacz K, Xu ZY, Loignon M, Alaoui-Jamali MA, and Panasci L (2004) Imatinib sensitizes CLL lymphocytes to chlorambucil. Leukemia 18:409-414.
3. Banáth JP and Olive PL (2003) Expression of phosphorylated histone H2AX as a surrogate of cell killing by drugs that create DNA double-strand breaks. Cancer Res 63:4347-4350.
4. Bello VE, Aloyz RS, Christodoulopoulos G, and Panasci LC (2002) Homologous recombinational repair vis-a-vis chlorambucil resistance in chronic lymphocytic leukemia. Biochem Pharmacol 63:1585-1588.
5. Bramson J, McQuillan A, Aubin R, Alaoui-Jamali M, Batist G, Christodoulopoulos G, and Panasci LC (1995a) Nitrogen mustard drug resistant B-cell chronic lymphocytic leukemia as an in vivo model for crosslinking agent resistance. Mutat Res 336:269-278.
6. Bramson J, McQuillan A, and Panasci LC (1995b) DNA repair enzyme expression in chronic lymphocytic leukemia vis-a-vis nitrogen mustard drug resistance. Cancer Lett 90:139-148.
7. Byrd JC, Stilgenbauer S, and Flinn IW (2004) Chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program, pp. 163-183.
8. Carlsson M, Totterman TH, Rosen A, and Nilsson K (1989) Interleukin-2 and a T cell hybridoma (MP6) derived B cell-stimulatory factor act synergistically to induce proliferation and differentiation of human B-chronic lymphocytic leukemia cells. Leukemia 3:593-601.
9. Celeste A, Fernandez-Capetillo O, Kruhlak MJ, Pilch DR, Staudt DW, Lee A, Bonner RF, Bonner WM, and Nussenzweig A (2003) Histone H2AX phosphorylation is dispensable for the initial recognition of DNA breaks. Nat Cell Biol 5:675-679.
10. Chan DW, Chen BP, Prithivirajsingh S, Kurimasa A, Story MD, Qin J, and Chen DJ (2002) Autophosphorylation of the DNA-dependent protein kinase catalytic subunit is required for rejoining of DNA double-strand breaks. Genes Dev 16:2333-2338.
11. Christodoulopoulos G, Malapetsa A, Schipper H, Golub E, Radding C, and Panasci LC (1999) Chlorambucil induction of HsRad51 in B-cell chronic lymphocytic leukemia. Clin Cancer Res 5:2178-2184.
12. Christodoulopoulos G, Muller C, Salles B, Kazmi R, and Panasci L (1998) Potentiation of chlorambucil cytotoxicity in B-cell chronic lymphocytic leukemia by inhibition of DNA-dependent protein kinase activity using wortmannin. Cancer Res 58:1789-1792.
13. Cowell IG, Durkacz BW, and Tilby MJ (2005) Sensitization of breast carcinoma cells to ionizing radiation by small molecule inhibitors of DNA-dependent protein kinase and ataxia telangiectasia mutated. Biochem Pharmacol 71:13-20.
14. De Silva IU, McHugh PJ, Clingen PH, and Hartley JA (2000) Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells. Mol Cell Biol 20:7980-7990.
15. Deriano L, Guipaud O, Merle-Beral H, Binet JL, Ricoul M, Potocki-Veronese G, Favaudon V, Maciorowski Z, Muller C, Salles B, et al. (2005) Human chronic lymphocytic leukemia B cells can escape DNA damage-induced apoptosis through the nonhomologous end-joining DNA repair pathway. Blood 105:4776- 4783.
16. Downs JA, Allard S, Jobin-Robitaille O, Javaheri A, Auger A, Bouchard N, Kron SJ, Jackson SP, and Cote J (2004) Binding of chromatin-modifying activities to phosphorylated histone H2A at DNA damage sites. Mol Cell 16:979-990.
17. Durocher D and Jackson SP (2001) DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme? Curr Opin Cell Biol 13:225-231.
18. Fernandez-Capetillo O, Lee A, Nussenzweig M, and Nussenzweig A (2004) H2AX: the histone guardian of the genome. DNA Repair (Amst) 3:959-967.
19. Jackson SP (2002) Sensing and repairing DNA double-strand breaks. Carcinogenesis 23:687-696.
20. Kashishian A, Douangpanya H, Clark D, Schlachter ST, Eary CT, Schiro JG, Huang H, Burgess LE, Kesicki EA, and Halbrook J (2003) DNA-dependent protein kinase inhibitors as drug candidates for the treatment of cancer. Mol Cancer Ther 2:1257-1264.
21. Loignon M, Fetni R, Gordon AJ, and Drobetsky EA (1997) A p53-independent pathway for induction of p21waf1cip1 and concomitant G1 arrest in UV-irradiated human skin fibroblasts. Cancer Res 57:3390-3394.
22. McHugh PJ, Spanswick VJ, and Hartley JA (2001) Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance. Lancet Oncol 2:483-490.
23. Muller C, Christodoulopoulos G, Salles B, and Panasci L (1998) DNA-dependent protein kinase activity correlates with clinical and in vitro sensitivity of chronic lymphocytic leukemia lymphocytes to nitrogen mustards. Blood 92:2213-2219.
24. Noll DM, Mason TM, and Miller PS (2006) Formation and repair of interstrand cross-links in DNA. Chem Rev 106:277-301.
25. Panasci L, Paiement JP, Christodoulopoulos G, Belenkov A, Malapetsa A, and Aloyz R (2001) Chlorambucil drug resistance in chronic lymphocytic leukemia: the emerging role of DNA repair. Clin Cancer Res 7:454-461.
26. Poot M, Schuster A, and Hoehn H (1991) Cytostatic synergism between bromodeoxyuridine, bleomycin, cisplatin and chlorambucil demonstrated by a sensitive cell kinetic assay. Biochem Pharmacol 41:1903-1909.
27. Riballo E, Kuhne M, Rief N, Doherty A, Smith GC, Recio MJ, Reis C, Dahm K, Fricke A, Krempler A, et al. (2004) A pathway of double-strand break rejoining dependent upon ATM, Artemis, and proteins locating to gamma-H2AX foci. Mol Cell 16:715-724.
28. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, and Bonner WM (1998) DNA doublestranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 273:5858-5868.
29. Rothkamm K, Kruger I, Thompson LH, and Lobrich M (2003) Pathways of DNA double-strand break repair during the mammalian cell cycle. Mol Cell Biol 23: 5706-5715.
30. Shiloh Y (2003) ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 3:155-168.
31. Shinohara ET, Geng L, Tan J, Chen H, Shir Y, Edwards E, Halbrook J, Kesicki EA, Kashishian A, and Hallahan DE (2005) DNA-dependent protein kinase is a molecular target for the development of noncytotoxic radiation-sensitizing drugs. Cancer Res 65:4987-4992.
32. Thiriet C and Hayes JJ (2005) Chromatin in need of a fix: phosphorylation of H2AX connects chromatin to DNA repair. Mol Cell 18:617-622.
33. Torres-Garcia SJ, Cousineau L, Caplan S, and Panasci L (1989) Correlation of resistance to nitrogen mustards in chronic lymphocytic leukemia with enhanced removal of melphalan-induced DNA cross-links. Biochem Pharmacol 38:3122-3123.
34. Veuger SJ, Curtin NJ, Richardson CJ, Smith GC, and Durkacz BW (2003) Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1. Cancer Res 63:6008-6015.
35. Willmore E, de Caux S, Sunter NJ, Tilby MJ, Jackson GH, Austin CA, and Durkacz BW (2004) A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia. Blood 103:4659-4665.
36. Zhu H and Gooderham NJ (2006) Mechanisms of induction of cell cycle arrest and cell death by cryptolepine in human lung adenocarcinoma a549 cells. Toxicol Sci 91:132-139.